secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0001437749-25-004891
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica Therapeutics appoints Daniel J. O'Connor to Board of Directors
------------------------------------------------------------------------

- Daniel J. O'Connor appointed to Board effective Feb 20, 2025; joins Audit and Nominating & Corporate Governance Committees.
- O'Connor previously served as CEO of Ambrx Biopharma, guiding it from $40M valuation to $2B acquisition by Johnson & Johnson in 14 months.
- He received option to purchase 64,242 common shares at fair market value, vesting quarterly over three years.
- Initial equity award for non-employee directors increased from 0.12% to 0.15% of outstanding common shares.
- Non-employee director annual equity award also increased from 0.06% to 0.075% of outstanding common shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774925004891/0001437749-25-004891-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774925004891/dmtp20250221_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-004891

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer